Quest Laboratories manufactures a diverse range of pharmaceutical formulations including antibiotics, antimalarials, and respiratory medications in various forms like tablets and liquids for ethical, generic, and over-the-counter markets. The company primarily serves government tenders and private distributors from its manufacturing facility in Madhya Pradesh.
The company lacks a durable moat as evidenced by its reliance on government tenders and generic formulations which are highly commoditized. While ROCE is high at 30%, the negative cash conversion and high debtor turnover suggest this is driven by aggressive working capital management rather than sustainable pricing power or brand strength.
Earnings have been largely reinvested into the business to fund capacity expansion and working capital, with a notable shift toward public equity markets in 2024 to fund further growth. No dividends have been paid recently, reflecting a focus on scaling the entity rather than returning capital to shareholders.
The investment collapsed as the negative cash conversion cycle finally strangled operations, proving that high ROCE was a mirage built on uncollectible receivables rather than real profit. The auditor's inability to verify inventory was a harbinger of the eventual massive write-down that wiped out book value. As the family-dominated board prioritized related-party remuneration over fiscal discipline, the company failed to transition from low-margin government tenders to branded products, leaving it a hollow shell of unrecovered debts and obsolete generic stock.
RichFakir rates Quest Laboratories Ltd's business quality as mediocre — 50/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Quest Laboratories Ltd is trading about 5% below our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Quest Laboratories Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Quest Laboratories Ltd's fair value is about ₹85 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →